Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Raymond James Upgrades Xencor, Inc. (XNCR) to Outperform
February 24, 2021 6:56 AM ESTRaymond James analyst Dane Leone upgraded Xencor, Inc. (NASDAQ: XNCR) from Market Perform to Outperform with a price target of $58.00.
The analyst comments "We are upgrading our recommendation of Xencor from Market Perform to Outperform and establishing a $58 price target. Our thesis is... More
Xencor (XNCR) Tops Q4 EPS by 14c, Revenues Beat
February 23, 2021 4:03 PM ESTXencor (NASDAQ: XNCR) reported Q4 EPS of ($0.24), $0.14 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $29.46 million.
"Throughout 2020, we advanced multiple clinical programs, introduced several new XmAb® bispecific technologies, and saw the progress of many partnered programs, including U.S. regulatory approval for tafasitamab, the second antibody with XmAb technology to achieve commercialization. Internally, early-stage clinical data have guided our decisions to advance several... More
